8-K: Corvus Pharma Halts $100M Public Stock Offering

Corvus Pharmaceuticals has suspended its planned $100 million common stock offering, with no shares sold prior to the halt.

Summary

• Corvus Pharmaceuticals, Inc. (the Company) notified Jefferies LLC on January 20, 2026, of the suspension of its registered underwritten public offering of common stock.
• The offering was for up to $100 million shares (ATM Shares) under a prospectus supplement filed on August 6, 2024, and a shelf Registration Statement on Form S-3 effective August 15, 2024.
• Prior to the suspension, no ATM Shares had been sold, and the full $100 million remained available for sale.
• The Company will not make any sales of common stock under the Sale Agreement unless a new prospectus supplement or registration statement is filed with the SEC.
• The Open Market Sale AgreementSM, dated August 6, 2024, between the Company and Jefferies, remains in full force and effect despite the suspension.

Sentiment

Score: 3

Explanation: The suspension of a planned capital raise is a negative event, suggesting potential funding challenges or unfavorable market conditions for the company. While the agreement remains in force, the immediate halt is a setback.

Negatives

• The Company has suspended its planned public offering of up to $100 million in common stock, indicating a potential inability to raise capital at desired terms or a shift in funding strategy.
• The suspension means the Company will not receive the anticipated capital from this offering until it is potentially reinstated with new filings.

Risks

• Uncertainties related to market conditions could impact the completion of public offerings on anticipated terms or at all.
• The Company's forward-looking statements involve assumptions that, if incorrect, could cause actual results to differ materially.
• Risks concerning the Company's business are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and other SEC filings.

Future Outlook

The Company's forward-looking statements include its anticipated public offering and future expectations, plans, and prospects. However, these are subject to market conditions and the completion of the public offering on anticipated terms or at all.

Management Comments

• Corvus Pharmaceuticals, Inc. has decided to suspend its registered underwritten public offering of common stock.

Industry Context

This announcement is a company-specific event related to Corvus Pharmaceuticals' capital raising efforts. It does not directly reflect broader industry trends but highlights the challenges companies can face in accessing capital markets, potentially due to specific company performance, market sentiment towards the sector, or general economic conditions.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to uncertainty regarding future capital raising and the Company's financial position.
• Creditors: May view the suspension as an indicator of increased financial risk, potentially affecting future credit terms.

Next Steps

• The Company may file a new prospectus supplement or registration statement with the SEC to resume sales of common stock under the Sale Agreement in the future.

Key Dates

Recommendation

The suspension of a planned $100 million public offering is a significant negative signal. It suggests the company either could not find buyers at an acceptable price, or faces other challenges that make a capital raise unfeasible at this time. This typically indicates financial pressure or a lack of investor confidence, which could lead to downward pressure on the stock price. Investors should consider selling to mitigate potential losses.

Keywords

Corvus Pharmaceuticals, CRVS, Public Offering, Stock Offering, Capital Raise, ATM Offering, Jefferies LLC, SEC Filing, Form 8-K, Biotechnology, Pharmaceuticals